Supplemental material
Open access
3,513
Views
2
CrossRef citations to date
0
Altmetric
Oncology
Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL
Matthias Calamiaa School of Pharmacy, Utrecht University, Utrecht, Netherlands;b Center of Health Outcomes and PharmacoEconomic Research, Tucson, AZ, USA
https://orcid.org/0000-0002-8921-7438
Ali McBrideb Center of Health Outcomes and PharmacoEconomic Research, Tucson, AZ, USA;c College of Pharmacy, University of Arizona, Tucson, AZ, USA;d Cancer Center, University of Arizona, Tucson, AZ, USA
https://orcid.org/0000-0002-9430-4675
Ivo Abrahamb Center of Health Outcomes and PharmacoEconomic Research, Tucson, AZ, USA;c College of Pharmacy, University of Arizona, Tucson, AZ, USA;d Cancer Center, University of Arizona, Tucson, AZ, USACorrespondence[email protected]
Pages 14-24
|
Received 20 Sep 2021, Accepted 04 Nov 2021, Published online: 06 Dec 2021
Related Research Data
Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.